Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Making Precision Medicine a Reality

Posted on April 24th, 2017 by in Chemistry

Precision medicine white paper

Precision medicine is no longer just a promising new development discussed only by medical professionals and industry insiders at conferences and in journals. In early 2015, former U.S. President Barack Obama announced the $215 million Precision Medicine Initiative (PMI), designed to accelerate biomedical research and drive the selection of promising therapies. Now precision medicine is being touted in inspiring TV commercials and written about in popular magazines – while at the same time, millions of people are becoming more excited about genetics through DNA testing services.

One of the reasons that precision medicine is capturing the public imagination is because it has already offered some new ways to fight cancer, an area where people are always hungry to see novel therapies, whether it is alternatives to traditional approaches like chemotherapy or brand new methods for tackling rare cancers. Precision medicine also speaks to our desire to have treatments that are more tailored to us, rather than the one-size-fits-all approach.

As the new white paper “From Concept to Reality: What’s Required to Achieve the Promise Held by Precision Medicine” explains, precision medicine is an evolving concept with a definition that sometimes varies, but one of its key ideas is that it aims to lead to better individual treatment. And at the heart of the precision approach is a more quantitative and mechanism-driven understanding of how diseases progress and how patients respond to intervention.

Precision medicine also has the potential to improve patient selection in clinical trials, leading to greater success in trials and regulatory approvals. In order to reach that potential, though, new technologies and tools, advances in research and curated bioresources will be required. Many of these developments are already in motion, so it is not so much a question of ‘if’ but ‘when’ – and how fast.

Read the white paper to learn more.


 

All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales